Capstone (CAPS) & Its Rivals Financial Contrast

Profitability

This table compares Capstone and its competitors’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Capstone	N/A	N/A	N/A
Capstone Competitors	-2,625.49%	-359.57%	-43.35%

Insider & Institutional Ownership

2.5% of Capstone shares are owned by institutional investors. Comparatively, 39.4% of shares of all “Pharmaceutical preparations” companies are owned by institutional investors. 59.1% of Capstone shares are owned by insiders. Comparatively, 14.0% of shares of all “Pharmaceutical preparations” companies are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Valuation and Earnings

This table compares Capstone and its competitors revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Capstone	$43.38 million	N/A	-1.50
Capstone Competitors	$440.95 million	-$69.10 million	-10.13

Capstone’s competitors have higher revenue, but lower earnings than Capstone. Capstone is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.

Volatility & Risk

Capstone has a beta of -0.83, meaning that its share price is 183% less volatile than the S&P 500. Comparatively, Capstone’s competitors have a beta of 10.18, meaning that their average share price is 918% more volatile than the S&P 500.

Summary

Capstone beats its competitors on 5 of the 8 factors compared.

About Capstone

Capstone Holding Corp., through its subsidiaries, engages in the distribution of masonry stone products in the United States. Its masonry stone products include manufactured and natural stone cladding products, natural stone landscape products and related goods for residential and commercial construction. The company was formerly known as Capstone Therapeutics Corp. and changed its name to Capstone Holding Corp. in February 2022. Capstone Holding Corp. was incorporated in 1987 and is headquartered in Tempe, Arizona. Capstone Holding Corp. operates as a subsidiary of BP Peptides, LLC.